New cell therapy shows promise for Hard-to-Treat blood cancer

NCT ID NCT07100067

Recruiting now Disease control Sponsor: Nanjing Legend Biotech Co. Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 06, 2026 · Updated 18 times

Summary

This study tests a new treatment called LCAR-F33S for people with multiple myeloma that has come back or stopped responding to other therapies. The treatment uses a patient's own immune cells, modified to attack cancer cells. The main goals are to check safety and find the best dose, while also seeing if it can shrink tumors. About 35 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Boren Hospital
NOT_YET_RECRUITING

Beijing, China

Contact Email: •••••@•••••
Institute of Hematology & Blood Diseases Hospital
RECRUITING

Tianjin, China
Institute of Hematology & Blood Diseases Hospital
RECRUITING

Tianjin, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
Wuhan Union Hospital
RECRUITING

Wuhan, China

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)